Halma FY profit jumps 22% but single tech customer accounts for 20% of sales

Halma posted a 23rd straight year of record adjusted profit, with revenue up 15% to £2.58 billion, adjusted EBIT up 22% to £594.5 million, and EPS up 21% to 114.05p. The board raised the full-year dividend 7% to 24.74p, while the company also disclosed a higher customer concentration risk: one unnamed technology customer now represents 20% of group revenue, up from 15%, and about half of Environmental & Analysis sales. Net debt increased to £769.1 million after a record £447 million acquisition spree.

Analysis

The key signal is not the headline growth rate; it is that a traditionally diversified compounder is becoming increasingly exposed to a single high-velocity technology platform. That creates a bifurcated setup: near term, the concentration can keep driving premium mix, margin expansion, and a stronger growth narrative; medium term, the market may begin to assign a “hidden customer dependency” discount if investors fear renegotiation, design displacement, or volume pull-forward. In other words, the earnings quality is improving mechanically while the franchise quality may be degrading structurally.

The second-order winner is the broader photonics / precision-sensing supply chain. When one customer reaches this level of spend, it usually implies multi-year roadmap lock-in, which tends to pull through component suppliers, contract manufacturers, and adjacent IP holders that are not yet priced for sustained demand. The loser is the customer base itself: if one account is ~half of a segment, every future product-cycle hiccup becomes a company-level growth event, raising the probability of larger quarterly swings than Halma’s historical profile would suggest.

The main catalyst to watch over the next 6-18 months is whether the company can grow the rest of the portfolio fast enough to dilute concentration while preserving margin. If photonics normalizes from very high growth toward the low-30s, headline growth could decelerate sharply even if the business remains healthy, which is exactly when quality multiple compression tends to hit. The contrarian view is that the market may be underestimating how long this concentration can actually persist: technical integration and qualification hurdles can make “winner-take-most” supplier relationships sticky for years, not quarters.

I would not fade the stock immediately on concentration alone, but I would treat this as a monitoring event rather than a clean compounder story. The setup favors owning the growth acceleration now, while using any rally to price in a slower second-half or FY27 deceleration scenario.

Key Decisions for Investors

• Long HLMA on pullbacks over the next 1-3 months; thesis is continued premium mix and margin leverage, with a stop if the market starts pricing in customer-loss risk before evidence of deceleration appears.
• Sell covered calls against an existing HLMA position into strength with 3-6 month tenor; monetizes elevated optimism while capping upside if the stock rerates on photonics momentum.
• Pair trade: long HLMA / short a lower-quality industrial compounder with weaker organic growth and less pricing power; favor the leg where earnings acceleration is still underappreciated over a purely defensive dividend name.
• Watch for FY27 guidance revisions and customer-concentration disclosures over the next 2 reporting cycles; if photonics growth guidance is reiterated but segment breadth does not improve, take profits on the long.
• If you want a cleaner expression of the theme, prefer diversified picks-and-shovels exposure to precision tech enablers rather than single-customer hardware names, because concentration risk is now the main hidden variable.